Somni: a randomized trial of an integrated digital platform for treating insomnia and insufficient sleep duration
Active Grant Awarded Last action
- Award ID
- R43HL184797
- Recipient
-
Pure Somni Corporation UEI FLNDC5JG7628
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $309,881
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date 21% complete
- Place of performance
- Madison, WI 53704, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services' National Institutes of Health, National Heart, Lung, and Blood Institute, awarded Pure Somni Corporation a grant of $309,881 on September 9, 2026, under the Cardiovascular Diseases Research program (Assistance Listing 93.837). The award funds a Phase I study of SOMNI, an integrated digital sleep health platform that combines remote CBT-I coaching, a structured educational curriculum, evidence-based sleep products, and objective sleep monitoring through wearables, for treating insomnia disorder and insufficient sleep duration. The study will formalize a sleep coach training program aligned with behavioral sleep medicine guidelines. It will also evaluate SOMNI's efficacy against SHUTI, a validated digital CBT-I platform, in a 120-participant randomized controlled trial with objective Oura Ring measurement and 6-month follow-up. Participants are aged 25-55 and have insomnia disorder (ISI >14) or insufficient sleep duration. Dollars obligated total $309,881, and the ultimate completion date is August 31, 2027. Place of performance is Madison, Wisconsin 53704, USA.
Description
- Abstract
- Insomnia disorder (ID) and insufficient sleep duration (ISD) affect 12% and 33% of american adults respectively, costing $280B yearly in healthcare and productivity losses. Current treatments face critical limitations: CBT-I is effective but inaccessible due to provider scarcity and focuses primarily on sleep continuity; digital CBT-I platforms suffer from poor adherence rates (20-57%); and sleeping pills introduce significant risks without long-term efficacy. Somni addresses these gaps with an integrated digital sleep health program that combines remote CBT-I coaching, a structured educational curriculum, evidence-based sleep products, and objective sleep monitoring through wearables. Preliminary data (N=136) showed a 35-minute sleep duration increase, 78% improved sleep quality, and 71% completion rate. This phase I study will: (1) formalize a rigorous sleep coach training program aligned with behavioral sleep medicine guidelines, and (2) evaluate somni's efficacy versus shuti (a validated dcbt-I platform) in a 120-participant randomized controlled trial with objective oura ring measurement and 6-month follow-up. Participants aged 25-55 with ID (ISI >14) and ISD (
Quick answers
Who received award R43HL184797?
R43HL184797 was awarded to Pure Somni Corporation by National Heart Lung and Blood Institute (National Institutes of Health) on September 9, 2026.
How much is award R43HL184797 worth?
$309,881 has been obligated on R43HL184797.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award